A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Actual Study Start Date: March 15, 2018
Estimated Primary Completion Date: May 25, 2021
Estimated Study Completion Date: June 29, 2022
Arm:
- Experimental: Atezolizumab + Bevacizumab
- Active Comparator: Sorafenib
| Category | Value |
|---|---|
| Date last updated at source | 2018-07-10 |
| Study type(s) | Interventional |
| Expected enrolment | 480 |
| Study start date | 2018-03-15 |
| Estimated primary completion date | 2021-05-25 |